David G. Dolan

816 total citations
28 papers, 588 citations indexed

About

David G. Dolan is a scholar working on Occupational Therapy, Health, Toxicology and Mutagenesis and Molecular Biology. According to data from OpenAlex, David G. Dolan has authored 28 papers receiving a total of 588 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Occupational Therapy, 10 papers in Health, Toxicology and Mutagenesis and 5 papers in Molecular Biology. Recurrent topics in David G. Dolan's work include Safe Handling of Antineoplastic Drugs (10 papers), Effects and risks of endocrine disrupting chemicals (8 papers) and Carcinogens and Genotoxicity Assessment (4 papers). David G. Dolan is often cited by papers focused on Safe Handling of Antineoplastic Drugs (10 papers), Effects and risks of endocrine disrupting chemicals (8 papers) and Carcinogens and Genotoxicity Assessment (4 papers). David G. Dolan collaborates with scholars based in United States, United Kingdom and Switzerland. David G. Dolan's co-authors include Edward V. Sargent, Bruce D. Naumann, Ellen C. Faria, Joel P. Bercu, Michael L. Dourson, Andrew Maier, Jeanine M. Buchanich, Gary M. Marsh, Jaime Madrigano and Daniel J. Caldwell and has published in prestigious journals such as American Journal of Epidemiology, Journal of Pharmaceutical Sciences and Environmental Research.

In The Last Decade

David G. Dolan

27 papers receiving 542 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David G. Dolan United States 14 238 227 93 75 55 28 588
Edward V. Sargent United States 16 199 0.8× 384 1.7× 130 1.4× 91 1.2× 73 1.3× 42 900
Sophie Ndaw France 16 138 0.6× 411 1.8× 55 0.6× 37 0.5× 133 2.4× 29 913
Lauri Pyy Finland 17 98 0.4× 398 1.8× 84 0.9× 40 0.5× 67 1.2× 34 751
Ellen C. Faria United States 10 135 0.6× 165 0.7× 59 0.6× 56 0.7× 16 0.3× 15 338
Jean‐François Latour France 6 236 1.0× 72 0.3× 81 0.9× 25 0.3× 49 0.9× 6 366
Milena Černá Czechia 24 367 1.5× 1.2k 5.3× 113 1.2× 77 1.0× 127 2.3× 63 1.7k
Stefano Dugheri Italy 18 47 0.2× 207 0.9× 97 1.0× 50 0.7× 93 1.7× 62 868
A. Colombi Italy 15 37 0.2× 233 1.0× 36 0.4× 26 0.3× 61 1.1× 46 591
Perumalla V. Rekhadevi India 12 126 0.5× 359 1.6× 68 0.7× 22 0.3× 130 2.4× 13 749
Božo Žonja Spain 12 308 1.3× 178 0.8× 24 0.3× 16 0.2× 107 1.9× 14 565

Countries citing papers authored by David G. Dolan

Since Specialization
Citations

This map shows the geographic impact of David G. Dolan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David G. Dolan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David G. Dolan more than expected).

Fields of papers citing papers by David G. Dolan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David G. Dolan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David G. Dolan. The network helps show where David G. Dolan may publish in the future.

Co-authorship network of co-authors of David G. Dolan

This figure shows the co-authorship network connecting the top 25 collaborators of David G. Dolan. A scholar is included among the top collaborators of David G. Dolan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David G. Dolan. David G. Dolan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Constantine, Lisa A., Natalie Burden, Todd Davidson, et al.. (2024). Evaluation of the EMA log kow trigger for fish BCF testing based on data for several human pharmaceuticals. Regulatory Toxicology and Pharmacology. 151. 105651–105651. 3 indexed citations
2.
Josephy, P. David, et al.. (2024). Evidence-based approaches to managing Canadian oil sands tailing pond waste: tighter regulations and greater transparency are needed. Zenodo (CERN European Organization for Nuclear Research). 2(1). 1 indexed citations
3.
Dolan, David G., et al.. (2024). Considerations and derivations of permitted daily exposure limits for impurities from intravitreal pharmaceutical products. Regulatory Toxicology and Pharmacology. 155. 105745–105745.
4.
Cohen, Joseph R., Marisa K. Joubert, Syeda Tabassum, et al.. (2024). Experimental validation of a parenteral permitted daily exposure value for cleaning-induced degradants from recombinant therapeutic proteins with in vitro immunogenicity assays. Journal of Pharmaceutical Sciences. 114(2). 866–877. 1 indexed citations
5.
Jolly, Robert A., Joel P. Bercu, David G. Dolan, et al.. (2022). Setting impurity limits for endogenous substances: Recommendations for a harmonized procedure and an example using fatty acids. Regulatory Toxicology and Pharmacology. 134. 105242–105242. 1 indexed citations
6.
Nashed-Samuel, Yasser, Stephanie Moore, David G. Dolan, et al.. (2022). Observation and Mitigation of Lamellar Silica Particles Formed in Pharmaceutical Products Packaged in Glass Vials. Journal of Pharmaceutical Sciences. 111(12). 3275–3286. 3 indexed citations
7.
Graham, Jessica, Alejandra Trejo‐Martin, Jakub Kostal, et al.. (2022). An Evaluation of the Occupational Health Hazards of Peptide Couplers. Chemical Research in Toxicology. 35(6). 1011–1022. 35 indexed citations
8.
Hawkins, W. Anthony, et al.. (2020). Deriving harmonised permitted daily exposures (PDEs) for paracetamol (acetaminophen) CAS #: 103-90-2. Regulatory Toxicology and Pharmacology. 115. 104692–104692. 5 indexed citations
9.
Martin, Elizabeth A., Susanne Glowienke, David G. Dolan, et al.. (2020). Considerations when deriving compound-specific limits for extractables and leachables from pharmaceutical products: Four case studies. Regulatory Toxicology and Pharmacology. 118. 104802–104802. 11 indexed citations
10.
Faria, Ellen C., et al.. (2016). Using default methodologies to derive an acceptable daily exposure (ADE). Regulatory Toxicology and Pharmacology. 79. S28–S38. 30 indexed citations
11.
Gould, Janet, et al.. (2016). Special endpoint and product specific considerations in pharmaceutical acceptable daily exposure derivation. Regulatory Toxicology and Pharmacology. 79. S79–S93. 20 indexed citations
12.
Dolan, David G., et al.. (2015). Threshold of toxicological concern (TTC) for developmental and reproductive toxicity of anticancer compounds. Regulatory Toxicology and Pharmacology. 72(3). 602–609. 19 indexed citations
13.
Caldwell, Daniel J., Birgit Mertens, Romain Journel, et al.. (2015). A risk-based approach to managing active pharmaceutical ingredients in manufacturing effluent. Environmental Toxicology and Chemistry. 35(4). 813–822. 27 indexed citations
14.
Bercu, Joel P., et al.. (2012). Advancing toxicology in RiskMAPP: Setting ADEs based on the subsequent drug substance. Regulatory Toxicology and Pharmacology. 65(1). 157–161. 11 indexed citations
15.
Bercu, Joel P. & David G. Dolan. (2012). Application of the threshold of toxicological concern concept when applied to pharmaceutical manufacturing operations intended for short-term clinical trials. Regulatory Toxicology and Pharmacology. 65(1). 162–167. 12 indexed citations
16.
Buchanich, Jeanine M., David G. Dolan, Gary M. Marsh, & Jaime Madrigano. (2005). Underascertainment of Deaths using Social Security Records: A Recommended Solution to a Little-Known Problem. American Journal of Epidemiology. 162(2). 193–194. 35 indexed citations
17.
Dolan, David G., Bruce D. Naumann, Edward V. Sargent, Andrew Maier, & Michael L. Dourson. (2005). Application of the threshold of toxicological concern concept to pharmaceutical manufacturing operations. Regulatory Toxicology and Pharmacology. 43(1). 1–9. 60 indexed citations
18.
Dolan, David G., Ada O. Youk, Gary M. Marsh, & Jeanine M. Buchanich. (2004). A 50-Year Historical Cohort Mortality Study of Workers in a Pharmaceutical Plant. Journal of Occupational and Environmental Medicine. 46(2). 161–166. 3 indexed citations
19.
Naumann, Bruce D., David G. Dolan, & Edward V. Sargent. (2004). Rationale for the Chemical-Specific Adjustment Factors Used to Derive an Occupational Exposure Limit for Timolol Maleate. Human and Ecological Risk Assessment An International Journal. 10(1). 99–111. 5 indexed citations
20.
Sargent, Edward V., et al.. (2002). The Importance of Human Data in the Establishment of Occupational Exposure Limits. Human and Ecological Risk Assessment An International Journal. 8(4). 805–822. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edward V. Sargent Breakdown of academic impact, for papers by Sophie Ndaw Breakdown of academic impact, for papers by Lauri Pyy Breakdown of academic impact, for papers by Ellen C. Faria Breakdown of academic impact, for papers by Jean‐François Latour Breakdown of academic impact, for papers by Milena Černá Breakdown of academic impact, for papers by Stefano Dugheri Breakdown of academic impact, for papers by A. Colombi Breakdown of academic impact, for papers by Perumalla V. Rekhadevi Breakdown of academic impact, for papers by Božo Žonja
Rankless by CCL
2026